bioAffinity Technologies, Inc.

BIAF Healthcare Diagnostics & Research

In the quarter to June 2026, revenue grew 19.0%, EPS grew 87.5%, free cash flow fell 23.7% and total debt rose 569.7%, each against the same quarter a year earlier.

3.73 0.23 −5.81%
Market cap
$5.1M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
2/9
Altman Z
−10.54
Beneish M
−5.49
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
0.47 0.33 3.04 0.72
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(1.27) (0.79) (5.34) (1.33)
P/B ratio
0.35 0.28 4.70 1.13
EV/Sales
(0.64) (0.61) 2.60 0.40
EV/EBITDA
0.44 0.37 0.00 0.00
EV/FCF
0.51 0.40 (1.35) (0.21)
Current Ratio
3.65 2.60 1.36 1.44
Net Debt/EBITDA
3.44 1.92 0.71 0.57
Debt/Equity
0.02 0.09 0.17 0.15
Earnings Yield
(707.62%) (1,334.92%) (307.03%) (898.56%)
Free Cash Flow Yield
(269.48%) (462.09%) (63.46%) (272.26%)
Free Cash Flow per Share
(34.83) (22.30) (10.78) (9.44)
Book value per Share
125.21 63.39 12.21 10.81
Free Cash Flow
(2.48) (2.56) (3.23) (3.29)
EV/EBIT
0.42 0.35 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026